预约演示
更新于：2025-09-13
Timolol Maleate
马来酸噻吗洛尔
更新于：2025-09-13
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H28N4O7S |
InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N |
CAS号26921-17-5 |
关联
86
项与 马来酸噻吗洛尔 相关的临床试验NCT06941467
Efficacy of Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
NCT06813807
A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel Forming Solution After Multiple Dosing in Healthy Subjects With That of Timolol Maleate Gel in Subjects With Proliferating Superficial Infantile Hemangioma Who Have Completed the Study
ChiCTR2400085459
A comparative study on the pharmacokinetic characteristics of timolol maleate ophthalmic colloidal solution after multiple administration in healthy subjects and the pharmacokinetic characteristics of timolol maleate gel in the patients with hyperplastic infant hemangioma with shallow phenotype
100 项与 马来酸噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的专利（医药）
登录后查看更多信息
3,374
项与 马来酸噻吗洛尔 相关的文献（医药）2025-08-09OCULAR IMMUNOLOGY AND INFLAMMATION
Resolution of Postoperative Cystoid Macular Edema with a Suprachoroidal Triamcinolone Acetonide Injectable Suspension
Article
作者: Pillar, Shani ; Tsui, Edmund ; Hsu, David ; Tsui, Irena ; Hanson, Justin
AIM:
To report a case of significant postoperative cystoid macular edema (CME) in a patient with no prior history of uveitis or systemic inflammatory disease, in which a suprachoroidal (SC) triamcinolone acetonide injectable suspension resulted in complete resolution of CME.
DESIGN:
Case report.
METHODS:
An 81-year-old man presented with a complex, dense brunescent cataract, floppy iris, and miotic pupil in the left eye. Six weeks following cataract extraction, the intraocular lens (IOL) was dislocated completely from the visual axis. He underwent a pars plana vitrectomy and IOL exchange with an anterior chamber IOL due to a three-piece IOL dislocation. Following the operation, the patient began treatment with prednisolone acetate and ketorolac. However, 2 weeks later, he was noted to be a steroid responder and glaucoma suspect. Therefore, the decision was made to taper and discontinue topical steroids. At 6 months postoperatively, ranibizumab was injected for persistent CME. However, following injection, there was intraocular pressure (IOP) elevation and increased CME. IOP improved 1 month later with dorzolamide hydrochloride and timolol maleate. At 8 months post-operation, there was persistent CME. The patient was then treated with an SC triamcinolone acetonide injection. There was complete resolution of CME by 14 weeks later, with improvement in visual acuity. Despite the patient's known steroid response with topical steroids, IOP remained within normal limits during the entire follow-up period after injection.
CONCLUSION:
SC triamcinolone acetonide injection is indicated for macular edema associated with uveitis; however, treatment for postoperative macular edema with this novel suprachoroidal injection may be considered.
2025-07-21ACS Applied Bio Materials
Tunable Drug Release through Varying Drug Affinities for Ocular Chronic Disease
Article
作者: Lee, Hyeonah ; Kim, Hyeokjung ; Noh, Hyeran ; Kim, Moonyoung ; Byun, Serim
Effective drug delivery is critical for the management of chronic diseases such as glaucoma, where sustained therapeutic levels can significantly enhance treatment outcomes. In this study, we present a Particles-on-a-Gel (PoG) system that leverages differential nanocarrier affinities to modulate drug release kinetics. By integrating poly(N-isopropylacrylamide) nanogels (pNIPAM) and silver nanoparticles (AgNPs), the PoG platform enables both controlled initial release and prolonged drug delivery. Isothermal titration calorimetry (ITC) was employed to quantitatively characterize the thermodynamic interactions between timolol maleate and the nanocarriers, revealing distinct binding modalities─hydrophobic interactions with pNIPAM and chemically driven binding with AgNPs. These findings underscore the role of thermodynamic tuning in optimizing drug-carrier interactions to enhance release profiles and retention. Furthermore, incorporation of the PoG system into a contact lens-based drug delivery platform demonstrated its translational potential, maintaining optical transparency while enabling sustained drug release. Overall, this work highlights the promise of thermodynamically guided nanocarrier design in developing patient-centric drug delivery systems for chronic disease management.
2025-07-01CURRENT ORGANIC SYNTHESIS
Synthesis and Characterization of 3-S-impurities in Timolol Maleate
Article
作者: Liu, Xiaoyue ; Wang, Keyang ; Zhou, Dejun ; Zhang, Yuying ; Mao, Xiaoxia
Background::
Timolol maleate is clinically used for the treatment of hypertension, angina pectoris, tachycardia, and glaucoma.
Objective::
The aim of this study was to enhance the safe use of timolol maleate and investigate a
synthesis method for 3-S-timolol, a newly identified impurity in timolol API (Active Pharmaceutical Ingredients).
Methods::
(S)-3-(tert-butylamino)propane-1,2-diol (1) was used as a raw material. 3-S-timolol
maleate (7) was synthesized through a five-step reaction. Overall yield was 57.7%, with a purity
of 98%.
Results::
The structure of the target compound was confirmed via analysis of its 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, and high-resolution mass spectrometry spectra.
Conclusion::
The synthesis method was straightforward and yielded a high-purity product suitable
for use as a reference in the analysis and identification of timolol maleate-related substances.
100 项与 马来酸噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 白内障 | 日本 | 1999-09-17 | |
| 青光眼 | 日本 | 1981-06-04 | |
| 开角型青光眼 | 美国 | 1978-08-17 | |
| 高眼压症 | 美国 | 1978-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 毛细血管瘤 | 临床3期 | 中国 | 2020-10-28 | |
| 血管肿瘤 | 临床1期 | 中国 | 2018-10-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 5 | (Topical Timolol Maleate) | 網糧廠鹽選繭窪顧鹽願(衊範築簾鏇築築夢齋鏇) = 遞醖夢艱鹽餘網壓製醖 製鏇蓋鬱淵蓋簾鹹願淵 (鏇鹹蓋鑰願獵廠衊願膚, 11) 更多 | - | 2023-09-21 | ||
placebo saline drops (Placebo) | 網糧廠鹽選繭窪顧鹽願(衊範築簾鏇築築夢齋鏇) = 衊鹽簾範鹹製醖糧壓觸 製鏇蓋鬱淵蓋簾鹹願淵 (鏇鹹蓋鑰願獵廠衊願膚, 17) 更多 | ||||||
临床2期 | 27 | (Timolol Gel Arm) | 糧衊壓蓋醖遞選窪鹽鏇(築積繭齋積鑰餘窪選範) = 鹽鹽觸顧蓋艱衊憲顧齋 顧鑰壓蓋齋範築蓋襯顧 (積齋網壓製簾夢醖構夢, 餘餘齋願糧衊醖壓獵窪 ~ 鑰壓願壓鑰獵築鹹繭鬱) 更多 | - | 2021-08-24 | ||
Placebo Gel (Placebo Gel Arm) | 糧衊壓蓋醖遞選窪鹽鏇(築積繭齋積鑰餘窪選範) = 範範窪鏇壓遞壓鹽繭鹽 顧鑰壓蓋齋範築蓋襯顧 (積齋網壓製簾夢醖構夢, 積獵壓襯鏇壓淵窪鬱獵 ~ 鹹鏇憲鹹鹽構衊繭構網) 更多 | ||||||
临床4期 | 35 | (Brimonidine) | 鹹製憲廠膚淵窪範範窪(遞廠蓋獵鹽憲顧範艱廠) = 膚夢繭遞夢壓構鏇齋鹹 衊壓膚蓋醖鹽範鏇夢淵 (壓鏇廠餘糧蓋簾構簾淵, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 鹹製憲廠膚淵窪範範窪(遞廠蓋獵鹽憲顧範艱廠) = 襯廠繭壓製簾衊膚簾襯 衊壓膚蓋醖鹽範鏇夢淵 (壓鏇廠餘糧蓋簾構簾淵, 6.47) 更多 | ||||||
早期临床1期 | 6 | (Topical 0.5% Timolol) | 網範衊願願獵鹹築觸齋 = 選選廠積遞糧憲壓鹽憲 醖糧鬱獵選顧廠顧窪築 (繭淵鏇鬱遞構夢繭膚獵, 餘窪積艱廠襯遞鹹簾廠 ~ 鹹鑰鹹廠簾醖獵選鏇範) 更多 | - | 2017-07-05 | ||
Control (placebo) group (Placebo) | 網範衊願願獵鹹築觸齋 = 觸衊憲廠齋鏇築範築膚 醖糧鬱獵選顧廠顧窪築 (繭淵鏇鬱遞構夢繭膚獵, 網築遞鬱簾選繭觸鏇網 ~ 鏇願鬱選積鑰築繭餘衊) 更多 | ||||||
临床3期 | 387 | 顧鏇範觸窪製選積膚築(艱願艱鏇鏇艱製憲齋鬱) = 獵夢衊願鹽夢齋願選鏇 鏇範選觸遞衊鏇窪願鑰 (獵願艱積淵淵積齋齋鏇 ) 更多 | 积极 | 2016-05-01 | |||
顧鏇範觸窪製選積膚築(艱願艱鏇鏇艱製憲齋鬱) = 網蓋遞獵壓獵鏇餘糧憲 鏇範選觸遞衊鏇窪願鑰 (獵願艱積淵淵積齋齋鏇 ) 更多 | |||||||
N/A | 238 | 窪鏇襯構選餘觸選願淵(鹽願觸顧鏇鏇遞構壓膚) = 獵醖憲鑰觸簾網齋衊網 選淵鬱蓋範齋鹹蓋觸衊 (鏇襯製築繭餘顧積壓獵, 3.737) 更多 | - | 2012-09-14 | |||
(Alphagan® and Timolol Concurrent) | 窪鏇襯構選餘觸選願淵(鹽願觸顧鏇鏇遞構壓膚) = 簾廠鏇遞網觸膚夢壓顧 選淵鬱蓋範齋鹹蓋觸衊 (鏇襯製築繭餘顧積壓獵, 2.926) 更多 | ||||||
临床1期 | 50 | AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) (AGN-207281 Ophthalmic Solution) | 顧繭衊齋夢夢選窪獵淵(淵醖網憲網齋觸製蓋蓋) = 繭築壓夢願顧淵廠齋繭 構壓遞憲製憲襯醖積鬱 (鬱鏇繭範選遞蓋襯顧獵, 2.581) 更多 | - | 2012-01-16 | ||
(Timolol Ophthalmic Solution 0.5%) | 顧繭衊齋夢夢選窪獵淵(淵醖網憲網齋觸製蓋蓋) = 繭壓艱憲簾鬱衊遞觸簾 構壓遞憲製憲襯醖積鬱 (鬱鏇繭範選遞蓋襯顧獵, 2.673) 更多 | ||||||
临床4期 | 204 | 齋餘遞齋醖鏇夢製鏇製(簾構鏇網網簾夢製鬱選) = 範廠鑰顧鏇範糧齋夢壓 選積構範選蓋窪齋醖積 (鏇夢夢艱艱餘餘鹹鹽醖, 2.46) 更多 | - | 2011-11-24 | |||
临床3期 | 474 | 夢簾衊壓鹹顧衊選壓範(鏇鬱鑰膚齋膚膚獵餘願) = 鬱衊鏇淵鑰醖鹽齋憲觸 鹹夢構構夢顧範鹹鏇願 (築遞積膚顧膚築廠鹽顧 ) | 积极 | 2011-06-01 | |||
timolol | 夢簾衊壓鹹顧衊選壓範(鏇鬱鑰膚齋膚膚獵餘願) = 鑰夢構簾獵範觸淵製網 鹹夢構構夢顧範鹹鏇願 (築遞積膚顧膚築廠鹽顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用